ZERBAXA (ceftolozane sulfate/tazobactam sodium)
NOSOCOMIAL BACTERIAL PNEUMONIA·+25
CUBIST PHARMACE
Indication
Ventilator-associated bacterial pneumonia
Ventilator-associated bacterial pneumonia is a severe lower respiratory tract infection of the lung parenchyma that develops 48 hours or more following endotracheal intubation and the initiation of invasive mechanical ventilation. Read more about Ventilator-associated bacterial pneumonia
9 drugs 8 manufacturers
Drugs that treat it
Common Ventilator-associated bacterial pneumonia therapies.
AVYCAZ (ceftazidime/avibactam sodium)
NOSOCOMIAL BACTERIAL PNEUMONIA·+10
FOREST PHARMACE
ZERBAXA (ceftolozane sulfate/tazobactam sodium)
NOSOCOMIAL BACTERIAL PNEUMONIA·+25
MERCK SHARP & D
AVYCAZ (ceftazidime/avibactam sodium)
BETA-LACTAMS·NOSOCOMIAL BACTERIAL PNEUMONIA·+10
Allergan
VIBATIV (telavancin HCl)
STAPHYLOCOCCUS NOSOCOMIAL PNEUMONIA·+6
THERA/CUMBERLAN
RECARBRIO (imipenem/cilastatin sodium/relebactam)
BETA-LACTAMS·NOSOCOMIAL BACTERIAL PNEUMONIA·+6
Merck Sharp & Dohme
FETROJA (cefiderocol sulfate tosylate)
BETA-LACTAMS·NOSOCOMIAL BACTERIAL PNEUMONIA·+7
SHIONOGI PHARMA
VIBATIV (telavancin HCl)
AGENTS TO TREAT RESISTANT GRAM POSITIVE ORGANISMS·STAPHYLOCOCCUS NOSOCOMIAL PNEUMONIA·+6
CUMBERLAND PHAR
ZERBAXA (ceftolozane sulfate/tazobactam sodium)
BETA-LACTAMS·NOSOCOMIAL BACTERIAL PNEUMONIA·+25
Merck Sharp & Dohme
Filter & compare in the drug finder →Opens the drug finder with Ventilator-associated bacterial pneumonia preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonVentilator-associated bacterial pneumonia is a severe lower respiratory tract infection of the lung parenchyma that develops 48 hours or more following endotracheal intubation and the initiation of invasive mechanical ventilation.
It predominantly affects critically ill patients in intensive care units, arising when natural airway defenses are compromised and bacterial pathogens—frequently multidrug-resistant Gram-negative bacilli or *Staphylococcus aureus*—colonize the endotracheal tube, form biofilms, and are microaspirated into the distal airways.
Clinically, the condition is characterized by new or progressive pulmonary infiltrates on chest imaging accompanied by systemic signs of infection, such as fever, leukocytosis or leukopenia, purulent sputum production, and declining oxygenation.
- nih.gov
Ventilator-associated bacterial pneumonia is a severe lower respiratory tract infection of the lung parenchyma that develops 48 hours or more following endotracheal intubation and the initiation of invasive mechanical ventilation
- merckmanuals.com
Ventilator-associated bacterial pneumonia is a severe lower respiratory tract infection of the lung parenchyma that develops 48 hours or more following endotracheal intubation and the initiation of invasive mechanical ventilation It predominantly affects critically ill patients in intensive care units, arising when natural airway defenses are compromised and bacterial pathogens—frequently multidrug-resistant Gram-negative bacilli or *Staphylococcus aureus*—colonize the endotracheal tube, form bi...
- nih.gov
It predominantly affects critically ill patients in intensive care units, arising when natural airway defenses are compromised and bacterial pathogens—frequently multidrug-resistant Gram-negative bacilli or *Staphylococcus aureus*—colonize the endotracheal tube, form biofilms, and are microaspirated into the distal airways
Personalize your experience
Follow Ventilator-associated bacterial pneumonia and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.